Related Experiment Video
Updated: Jan 10, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Hemophilia: Reducing Treatment Burden with Pen Devices
Chandrakala Shanmukaiah1, Parul Bhatt2, Kundan Mishra3
1Professor and Head, Department of Clinical Hematology, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, Maharashtra, India, Corresponding Author.
None:
Hemophilia is a coagulation disorder caused by deficient or absent clotting factors. It is a chronic disease that starts from birth and requires lifelong intravenous administration of antihemophilic factors. Healthcare professionals (HCPs), patients living with hemophilia, and their caregivers have reported concerns regarding the challenges associated with the intravenous route and the deterioration in their quality of life (QoL) due to the frequently repeated infusions necessary to maintain the desired levels of clotting factors. Patients with hemophilia and their caregivers have often voiced their need for easier methods of treatment administration, similar to the way insulin is delivered subcutaneously using a pen. Subcutaneous injection using a pen device is a known way to improve treatment compliance and adherence in patients with chronic diseases. The recent introduction of pen devices for hemophilia treatment administration is expected to reduce the administration burden and improve QoL. The narrative review presents the advantages of pen devices and patient and caregiver attitudes toward these newly introduced pen devices in hemophilia.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

